Actualizado 08/11/2007 00:06 CET
- Comunicado -

Fenofibrate - First Lipid Modifying Agent Shown to Protect Diabetic Eye

SYDNEY, November 7 /PRNewswire/ -- In the Lancet, on Tuesday November, 6th new results of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) 2007 clinical trial have been published and presented on the same date at a press conference held during the AHA.

-- First lipid modifying agent shown to reduce the need for treatment of the leading causes of blindness and deteriorating vision in patients with type 2 diabetes

-- Reduces need for laser treatment in patients with and without known diabetic retinopathy

-- Significantly decreases progression of diabetic eye disease

If you are interested in knowing more about this breaking news and in getting additional information on the management of microvascular complications in type 2 diabetes, we are pleased to invite you to visit "the Field Study Investigators Website", where you will have the opportunity to login to the Webcast of the press conference.

Please click below: http://www.thefieldtrial.org

Media Contact: Beth Quinlivan, University of Sydney, Ph: +61-2-9036-6528, Mob: +61-0-419-229-134, bquinlivan@med.usyd.edu.au

Mejora la comunicación de tu empresa con Europa Press Comunicación

Lo más leído

  1. 1

    Las naves Voyager detectan nueva física única del medio interestelar

  2. 2

    Abascal comunica al Congreso un préstamo de 736.000 euros para comprar su nueva casa

  3. 3

    El Congreso aprueba por amplia mayoría los presupuestos del Gobierno de Sánchez e Iglesias

  4. 4

    La juez deja en libertad al bailarín Rafael Amargo y los otros tres detenidos

  5. 5

    Profesores catalanes avisan por carta al PSOE: "No es que el castellano vaya a desaparecer, es que es ya residual"